Floatz logo

Midazolam

Gastroesophageal Reflux Disease

Children's Mercy Hospital Kansas CitySmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

1 Active assets in the Gastroesophageal Reflux Disease cohort.

View all 17

Same molecule, other indications

Midazolam is also rated in:

neuralgiaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
gastrointestinal stromal tumorActive
BBB
Indicative · Phase 4
75 / 100
View asset →
choledocholithiasisActive
BBB
Indicative · Phase 4
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →